SYRS vs. SGMT, AMLX, BPTS, ANVS, VTGN, IXHL, IMAB, RGLS, KPTI, and CRVO
Should you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include Sagimet Biosciences (SGMT), Amylyx Pharmaceuticals (AMLX), Biophytis (BPTS), Annovis Bio (ANVS), Vistagen Therapeutics (VTGN), Incannex Healthcare (IXHL), I-Mab (IMAB), Regulus Therapeutics (RGLS), Karyopharm Therapeutics (KPTI), and CervoMed (CRVO). These companies are all part of the "pharmaceutical preparations" industry.
Sagimet Biosciences (NASDAQ:SGMT) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking.
Sagimet Biosciences has a net margin of 0.00% compared to Sagimet Biosciences' net margin of -1,656.34%. Syros Pharmaceuticals' return on equity of 0.00% beat Sagimet Biosciences' return on equity.
Sagimet Biosciences has higher earnings, but lower revenue than Syros Pharmaceuticals.
Syros Pharmaceuticals received 349 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 100.00% of users gave Sagimet Biosciences an outperform vote while only 63.94% of users gave Syros Pharmaceuticals an outperform vote.
Sagimet Biosciences presently has a consensus target price of $41.50, indicating a potential upside of 922.17%. Syros Pharmaceuticals has a consensus target price of $14.33, indicating a potential upside of 184.39%. Given Syros Pharmaceuticals' higher possible upside, research analysts clearly believe Sagimet Biosciences is more favorable than Syros Pharmaceuticals.
87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 10.5% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Sagimet Biosciences had 2 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 2 mentions for Sagimet Biosciences and 0 mentions for Syros Pharmaceuticals. Syros Pharmaceuticals' average media sentiment score of 0.67 beat Sagimet Biosciences' score of 0.00 indicating that Sagimet Biosciences is being referred to more favorably in the media.
Summary
Sagimet Biosciences beats Syros Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
Get Syros Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syros Pharmaceuticals Competitors List
Related Companies and Tools
